Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL834551 | 0.79 | TAAR1 (0.73) | TAAR1MAOBCALM1AOC3SIGMAR1 | |
| SCHEMBL1295195 | 0.79 | TAAR1 (0.55) | TAAR1MAOBCALM1AOC3SIGMAR1 | |
| SCHEMBL9826749 | 0.79 | TAAR1 (0.55) | TAAR1MAOBCALM1AOC3SIGMAR1 | |
| SCHEMBL467216 | 0.78 | TAAR1 (0.54) | TAAR1MAOBCALM1SIGMAR1IDO1 | |
| Water SCHEMBL10445073 | 0.77 | TAAR1 (0.52) | TAAR1MAOBCALM1SIGMAR1IDO1 | |
| SCHEMBL6835490 | 0.76 | TAAR1 (0.61) | TAAR1MAOBCALM1AOC3SIGMAR1 | |
| SCHEMBL4634 | 0.76 | TAAR1 (1.00) | TAAR1MAOBCALM1AOC3IDO1 | |
| SCHEMBL365644 | 0.76 | TAAR1 (0.61) | TAAR1MAOBCALM1AOC3SIGMAR1 | |
| SCHEMBL244070 | 0.75 | CALM1 (0.79) | TAAR1MAOBCALM1AOC3SIGMAR1 | |
| SCHEMBL4254058 | 0.75 | CALM1 (0.72) | TAAR1MAOBCALM1AOC3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1761509-B1 | SUBSTITUTED CYCLOALKYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2011-05-04 | — | — | EP | disclosed |
| US-7718670-B2 | Quinuclidine amide derivatives | LABORATORIOS ALMIRALL S.A (ES) | 2010-05-18 | — | — | US | disclosed |
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7563806-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-21 | — | — | US | disclosed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | disclosed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | disclosed |
| US-7423035-B2 | Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1595873-A1 | Substituted cycloalkyl derivatives for the treatment of respiratory diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| EP-1519933-A1 | QUINUCLIDINE AMIDE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | disclosed |
| US-5641765-A | TREATS PROSTATIC ADENOCARCINOMA, BENIGN PROSTATE HYPERTROPHY; ANTAGONSIT, ANTAGONISM | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| US-5641877-A | 17-α and 17-β substituted acyl-3-carboxy-3, 5-dienes and use in inhibiting 5-α-reductase | SMITHKLINE BEECHAM CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0669932-A4 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE. | SMITHKLINE BEECHAM CORP (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669932-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994011386-A1 | 17-ALPHA AND 17-BETA SUBSTITUTED ACYL-3-CARBOXY-3,5-DIENES AND USE IN INHIBITING 5-ALPHA-REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234316-A1 | Quinuclidine Amide Derivatives | CHRM3, CHRM2, CHRM1 | TAAR1 192/4885MAOB 764/4885CALM1 861/4885 |
| US-20080146554-A1 | Substituted Cycloalkyl Derivatives, Process for the Manufacture thereof and Use thereof as Medicament | CHRM1, CHRM2, CHRM3 | TAAR1 419/4885MAOB 852/4885CALM1 2078/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | TAAR1 2993/4885MAOB 2233/4885CALM1 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.